BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18506988)

  • 1. [Pyoderma gangrenosum is 100 years old. From Louis Brocq to biotherapies].
    Farhi D; Wallach D; Avril MF
    Rev Prat; 2008 Feb; 58(4):457-61. PubMed ID: 18506988
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinical and histopathological description of geometric phagedenism (pyoderma gangrenosum) by Louis Brocq one century ago.
    Farhi D
    Arch Dermatol; 2008 Jun; 144(6):755. PubMed ID: 18559764
    [No Abstract]   [Full Text] [Related]  

  • 3. [Infliximab for a girl with refractory pyoderma gangrenosum].
    Nozawa T; Hara R; Kinoshita J; Sano F; Miyamae T; Imagawa T; Mori M; Hirokado M; Takahashi K; Inayama Y; Yokota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Dec; 31(6):454-9. PubMed ID: 19122376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyoderma gangrenosum--rebel without a cure?
    Jacob SE; Weisman RS; Kerdel FA
    Int J Dermatol; 2008 Feb; 47(2):192-4. PubMed ID: 18211497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
    Tanczos BT; Baumgart DC
    Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study.
    Rousset L; de Masson A; Begon E; Villani A; Battistella M; Rybojad M; Jachiet M; Bagot M; Bouaziz JD; Lepelletier C
    J Am Acad Dermatol; 2019 Apr; 80(4):1141-1143. PubMed ID: 30342166
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents.
    Duchini G; Itin P; Arnold A
    Adv Skin Wound Care; 2011 May; 24(5):217-20. PubMed ID: 21505282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
    Stichweh DS; Punaro M; Pascual V
    Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory pyoderma gangrenosum treated with infliximab in an infant.
    Campos-Muñoz L; Conde-Taboada A; Aleo E; Toledano E; López-Bran E
    Clin Exp Dermatol; 2014 Apr; 39(3):336-9. PubMed ID: 24635074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab as a treatment for recalcitrant pyoderma gangrenosum.
    Singh M; Andrew SM; Lear JT
    Clin Exp Dermatol; 2004 Mar; 29(2):196-7. PubMed ID: 14987282
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
    Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
    Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.
    López San Román A; Bermejo F; Aldanondo I; Carrera E; Boixeda D; Muñoz Zato E
    Rev Esp Enferm Dig; 2004 Jun; 96(6):420-2; 422-4. PubMed ID: 15230672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease.
    Batres LA; Mamula P; Baldassano RN
    J Pediatr Gastroenterol Nutr; 2002 May; 34(5):558-60. PubMed ID: 12050585
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
    Cocco A; Angelucci E; Viscido A; Caprilli R
    Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
    [No Abstract]   [Full Text] [Related]  

  • 15. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
    Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
    Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Presentation of pyoderma gangraenosum in a dermatologic atlas of the early 19th century].
    Kuner N; Hartschuh W
    Hautarzt; 2000 Jul; 51(7):519-23. PubMed ID: 10969411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: don't forget the role of cyclosporin.
    Sinagra E; Orlando A; Renna S; Maida M; Cottone M
    Inflamm Bowel Dis; 2012 Aug; 18(8):E1594-5. PubMed ID: 22038892
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
    Hubbard VG; Friedmann AC; Goldsmith P
    Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Infliximab treatment of peristomal pyoderma gangrenosum in ulcerative colitis].
    Nybaek H; Jemec GB
    Ugeskr Laeger; 2005 Aug; 167(32):2920-1. PubMed ID: 16109221
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab for peristomal pyoderma gangrenosum.
    Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
    Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.